MedTrace Logo

Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

NCT07080385 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-04-22

No results posted yet for this study

Summary

The overall objective of this study is to evaluate the pharmacokinetics (PK), efficacy, and safety of encaleret in pediatric participants from birth to 17 years of age with ADH1.

Conditions

  • Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Interventions

DRUG

Encaleret

Oral tablets, age-appropriate pediatric formulation (currently under development).

Sponsors & Collaborators

  • Calcilytix Therapeutics, Inc., a BridgeBio company

    lead INDUSTRY

Principal Investigators

  • Calcilytix Medical Director · Calcilytix Therapeutics, Inc., a BridgeBio company

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
0 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-30
Primary Completion
2028-12-31
Completion
2030-12-31
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07080385 on ClinicalTrials.gov